40 related articles for article (PubMed ID: 38574938)
21. PML nuclear bodies and chromatin dynamics: catch me if you can!
Corpet A; Kleijwegt C; Roubille S; Juillard F; Jacquet K; Texier P; Lomonte P
Nucleic Acids Res; 2020 Dec; 48(21):11890-11912. PubMed ID: 33068409
[TBL] [Abstract][Full Text] [Related]
22. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.
Van Damme E; Laukens K; Dang TH; Van Ostade X
Int J Biol Sci; 2010 Jan; 6(1):51-67. PubMed ID: 20087442
[TBL] [Abstract][Full Text] [Related]
23. The Role of Promyelocytic Leukemia Nuclear Bodies During HPV Infection.
Guion LG; Sapp M
Front Cell Infect Microbiol; 2020; 10():35. PubMed ID: 32154186
[TBL] [Abstract][Full Text] [Related]
24. Role and fate of PML nuclear bodies in response to interferon and viral infections.
Regad T; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7274-86. PubMed ID: 11704856
[TBL] [Abstract][Full Text] [Related]
25. The role of SUMOylation in ageing and senescent decline.
Princz A; Tavernarakis N
Mech Ageing Dev; 2017 Mar; 162():85-90. PubMed ID: 28088449
[TBL] [Abstract][Full Text] [Related]
26. Double-edged role of PML nuclear bodies during human adenovirus infection.
Hofmann S; Stubbe M; Mai J; Schreiner S
Virus Res; 2021 Apr; 295():198280. PubMed ID: 33370557
[TBL] [Abstract][Full Text] [Related]
27. The functional roles of PML nuclear bodies in genome maintenance.
Chang HR; Munkhjargal A; Kim MJ; Park SY; Jung E; Ryu JH; Yang Y; Lim JS; Kim Y
Mutat Res; 2018 May; 809():99-107. PubMed ID: 28521962
[TBL] [Abstract][Full Text] [Related]
28. PML nuclear body biogenesis and oligomerization-driven leukemogenesis.
Li Y; Ma X; Meng G
Blood Sci; 2020 Jan; 2(1):7-10. PubMed ID: 35399865
[TBL] [Abstract][Full Text] [Related]
29. [Post-translational Modifications of PML in Regulating the Functions of Nuclear Bodies --Review].
Ma XF; Tan Y; Li SF; Jin W; Wang KK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1696-1700. PubMed ID: 31607334
[TBL] [Abstract][Full Text] [Related]
30. The interactions between PML nuclear bodies and small and medium size DNA viruses.
Ryabchenko B; Šroller V; Horníková L; Lovtsov A; Forstová J; Huérfano S
Virol J; 2023 May; 20(1):82. PubMed ID: 37127643
[TBL] [Abstract][Full Text] [Related]
31. Interplay between RNA Viruses and Promyelocytic Leukemia Nuclear Bodies.
Neerukonda SN
Vet Sci; 2021 Mar; 8(4):. PubMed ID: 33807177
[TBL] [Abstract][Full Text] [Related]
32. PML nuclear bodies.
Lallemand-Breitenbach V; de Thé H
Cold Spring Harb Perspect Biol; 2010 May; 2(5):a000661. PubMed ID: 20452955
[TBL] [Abstract][Full Text] [Related]
33. Unravelling the molecular interplay: SUMOylation, PML nuclear bodies and vascular cell activity in health and disease.
Berkholz J; Karle W
Cell Signal; 2024 Jul; 119():111156. PubMed ID: 38574938
[TBL] [Abstract][Full Text] [Related]
34. A Tale of Usurpation and Subversion: SUMO-Dependent Integrity of Promyelocytic Leukemia Nuclear Bodies at the Crossroad of Infection and Immunity.
Patra U; Müller S
Front Cell Dev Biol; 2021; 9():696234. PubMed ID: 34513832
[TBL] [Abstract][Full Text] [Related]
35. PML Nuclear bodies: the cancer connection and beyond.
Abou-Ghali M; Lallemand-Breitenbach V
Nucleus; 2024 Dec; 15(1):2321265. PubMed ID: 38411156
[TBL] [Abstract][Full Text] [Related]
36. PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.
Sahin U; de Thé H; Lallemand-Breitenbach V
Nucleus; 2014; 5(6):499-507. PubMed ID: 25482067
[TBL] [Abstract][Full Text] [Related]
37. Interferon, restriction factors and SUMO pathways.
El-Asmi F; McManus FP; Thibault P; Chelbi-Alix MK
Cytokine Growth Factor Rev; 2020 Oct; 55():37-47. PubMed ID: 32591223
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
